Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Enlivex Ltd. - Ordinary Shares
(NQ:
ENLV
)
2.500
-1.760 (-41.31%)
Streaming Delayed Price
Updated: 11:00 AM EDT, Jul 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Enlivex Ltd. - Ordinary Shares
< Previous
1
2
3
4
Next >
Enlivex Announces $400,000,000 Private Placement
Today 8:00 EDT
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
July 20, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
July 13, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
July 07, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume
June 24, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
June 22, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
June 15, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
June 02, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
June 01, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board
May 28, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity
May 27, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
May 18, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
May 15, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
April 30, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
April 28, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
April 23, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
April 21, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Posts $1.23B Profit (Net Income) For Fiscal 2025
March 26, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt
March 26, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
March 25, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
March 24, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
March 23, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Off The Hook Yachts and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
March 20, 2026
Via
ACCESS Newswire
Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
February 10, 2026
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
RedChip Fintech & DATS Conference Replays Now Available Featuring Public Companies Shaping the Future of Digital Finance
February 09, 2026
Via
ACCESS Newswire
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange
January 26, 2026
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq
January 23, 2026
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on KuCoin, a Leading Cryptocurrency Exchange
January 07, 2026
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development
December 04, 2025
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement
November 26, 2025
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
